Recombination of human erythytocytoples: Classics and Innovations.

In the 1980s, genetically engineered biosynthetic technology opened a chapter in the era of human biopharmaceuticals.
Following the birth of human insulin, the first genetically engineered hematopoietic growth factor, recombined human erythione cell production (rHuEPO), was successfully developed in 1985 and approved for large-scale production for clinical practice in 1989, becoming a landmark classic biopharmaceutical in the history of biopharmaceutical development and human insulin shoulder-to-shoulder, and creating more opportunities for life for anaemic patients worldwide.
Compared to recombined human insulin, the process of rHuEPO is more complex: in gene recombination, the small molecular weight and simple molecular structure of recombined human insulin can be expressed directly in E. coli, while erythrocyte production is known to have a large number of glycosylated molecules and complex three-dimensional structures, which need to be expressed in mammalian cell lineages.
rHuEPO brings together nearly a century of research and development efforts by scientists such as Carnot and Randy Kaufman, and its large-scale production has rapidly advanced genetic engineering from the era of simple primary and endoenvironomy to the era of advanced myristocytes, i.e. mammalian cell expression systems, becoming the ancestors of mammalian cell expression gene engineering biopharmaceuticals, and facilitating the development of other series of hematogenesis biopharmaceuticals.
erythropoietin: an indispensable cytokine for human hematopoietic blood, a key target for anemia erythropoietin (erythropoietin, or EPO) is an indispensable cytokine for human hematopoietic.
Adults normally secrete erythrene from the kidneys and regulate the whole process of bone marrow hematopoirture to produce red blood cells, including promoting the proliferation, differentiation and maturation of bone marrow erythrin cells and the release of meshed red blood cells from the bone marrow into the blood and other important links, it can be seen that erythrene is essential for the production of red blood cells.
The lack of erythroid deficiency, reduced or increased production (e.g., impaired or decreased kidney function, bone marrow damage caused by chemotherapy of tumors, various operations, etc.) can directly affect red blood cell production and lead to anemia, so supplementation with exogenetic rHuEPO in these cases is an essential means of correcting anemia."
The role of erythrocyte-promoting erythrocytes weak is a common symptom that long-term problems in anemia patients, if not corrected in time, will cause dizziness, tinnitus, inattence, drowsiness, loss of appetite and even heart enlargement and other series of symptoms, severe cases may also appear liver, spleen enlargement and a variety of postoperative infections, prolonged hospital stay and other sequelae.
The prevalence of anaemia in our country is as high as 20 per cent, which means that one in five people is anaemic, while less than 20 per cent of patients with mild anaemia are treated and only 1/2 of those with extreme anaemia are clinically treated.
August 18, 2018, authoritative academic institutions and multidisciplinary experts jointly initiated the establishment of "818 China Anemia Day" to enhance the care and attention of the whole society to anaemia patients, with a view to helping more anaemia patients return to a dynamic state and enjoy a better day.
Innovation: Exogenetative erythrene supplement can not only treat anemia, but also have the protective effect of heart, kidney and other multi-organ tissue Exogenetative erythrene can not only be combined with the high affinity of hematopoesic tissue, but also with many non-hematopoirturic tissue erythythione ligands in the human body.
refore, the treatment of rHuEPO not only improves the oxygen supply and function of tissues such as the heart and kidneys by increasing hemoglobin, but also protects the heart, kidneys and other multi-organ tissues.
it is well known that renal fibrosis is the pathological basis and result of various chronic kidney disease progressions.
Exogenetic erythroid enters the body and binds to the erythroid-promoting body of interlengine cells and initiates a series of signaling path paths such as STAT5, PI3K/AKT, MAPK, which activate and combine to inhibit the production of interlengine fibroblasts, etc. and prevent the process of renal fibrosis.
, the complementary treatment of rHuEPO can help patients achieve kidney protection while improving their kidney oxygen supply.
In addition, exogenetic erythrene also binds to myocardial cells' erythrene-promoting bodies and activates signaling pathways such as PI3K/AKT to promote the proliferation of myocardial cells and prevent apoptosis of myocardial cells, which can be clinically shown to improve patients' symptoms such as heart failure, astrology, angina, etc.
clinical studies have shown that the supplementation of extrophic erythroid can improve some heart function-related indicators in patients with anemia, such as left atrial mass index (LVMi), left atrial throid index (LVDd), left atrial blood score (LVEF), cerebral sodium peptides, etc., so the treatment of rHuEPO can help patients prevent chronic heart failure, angina, myocardial infarction, etc., and improve the patient's motor ability and quality of life.
Exogenous erythromycin can also be combined with endophyte erythrin receptors in blood vessels to prevent tissue isnemic hypoxia caused by abnormal vascular contractions, such as regulating vascular tension;
, how the treatment of rHuEPO can help anaemic patients achieve multiple benefits is becoming a new focus of clinical research.
Exogenetic erythrene can be combined with the body's multi-organ tissue EPO subject (EPOR) to play a corresponding protective role anemia treatment drugs, recombinant human erythytocytopenia treatment is still irreplaceable nearly half a century on the market rHuEPO greatly reduced blood infusion rate, saving social medical resources, while bringing millions of anemia patients a high-quality life, become an anemia patients indispensable helper.
recent years, the emergence of low oxygen-induced factor-proline hydroxyase inhibitor (HIF-PHI) has promoted renewed attention to anemia.
HIF-PHI improves the expression of hypooxygenation factors (HIF) by inhibiting the activity of proline hydroxyase to simulate hypoxia models in the body, and then increases the expression of erythrene (EPO) by increasing the level of HIF to achieve the therapeutic goal of improving anemia.
Although the role of HIF-PHI upward erythrenin does not directly supplement erythrene to come directly and simply, and may be due to long-term increase in the level of low oxygen induction factors to patients with some long-term potential harm, but as a complementary to anemia treatment, HIF-PHI is also clinically tried to be used in some stubborn anemia patients.
although HIF-PHI drugs are already available in China, long-term cardiovascular safety outcomes in the U.S. for their HIF-PHI clinical studies have been questioned and have not yet been approved and approved by the FDA.
still need to be careful for patients who need long-term use of anemia drugs.
However, the introduction of HIF-PHI has promoted the academic community and the public's renewed attention and attention to anaemia patients, it has been found that anemia causes a series of pathophysiological disorders, significantly reduce the quality of life and survival rate of patients, and worsen the progress of various diseases, especially cancer patients, how to comprehensively assess the psychological harm and social impact of anemia on patients, need to be further explored.
Ibio (recombination of human erythyme progenition): creating a legend in the Chinese industry in the United States, rHuEPO prices have remained high so far, about 1200 yuan / branch / 10,000 units, is the United States ordinary anemia patients are not a step forward in biopharmaceuticals.
And in China, in order to enable the vast number of anaemic patients to afford high-quality and low-cost erythrene, biopharmaceuticals started with the domestic leader - Sansheng Pharmaceuticals in the 1990s in response to the government's call, put forward "everyone can afford China's own production of high-quality erythrene" social responsibility goals.
1998, Sansheng Pharmaceuticals' recombined erythytocyte progenitor Ibio was approved for listing by the CFDA, becoming the first local rHuEPO to go public in China.
price is only one-third of that of imported products.
China's erythrin market, driven and led by Ibio, has grown from millions in the late 1990s to 700 million yuan in 2010 and 2.5 billion yuan in 2019.
Sansheng Pharmaceuticals, as the absolute leader of the erythrin market, has a steady market share of more than 40% for many years, taking the lead in creating a legend in the industry of local biologics to beat imported biological agents, and becoming a proud role model for national biopharmaceutical companies.
2012-2019, China's erythrene market and Sansheng Pharmaceuticals erythrene market share Ofbio (rHuEPO) by virtue of its stable quality, high degree of glycosylation, chemical and chemical properties and other characteristics, but also become a well-deserved domestic biopharmaceutical quality model.
2011, Sansheng Pharmaceuticals took the initiative to upgrade the production quality standard of Ibio to the European Pharmacopeia standard in order to further achieve the goal of "producing high-quality recombinant bioproteins".
high quality and favorable prices, Exo has been approved for listing in 15 other countries around the world, in addition to China.
as china's first pioneer of genetically engineered biopharmaceuticals, Sansheng Pharmaceuticals has led local enterprises in the relentless pursuit of research and development and production of high-quality, high-efficacy biopharmaceuticals.
, even uninsured patients in China can afford high-quality rHuEPO treatment for about $12 a day, while U.S. patients spend about 170 yuan a day on erythrene therapy.
In 2018, the Chinese government included the efficacy, long-term use of safe and inexpensive rHuEPO in the "National List of Essential Medicines", and since then ordinary people have been able to afford and buy high-quality Ibio everywhere in primary health care institutions.
Sansheng Pharmaceuticals finally realized the dream of "high-quality erythrene produced by everyone in China" for Chinese anemia patients, and became the pride of the national industry.
Ibio: Patient-centered, innovative to help anaemia patients in an increasingly rich anemia treatment practice, rHuEPO has always been by virtue of its mechanism of irreplaceability, stable and long-term use of safety, and help society to significantly save blood resources and other advantages to become an unshakable basic treatment option for chronic anemia treatment.
sansheng pharmaceutical innovation to pursue and achieve the "patient-centered" concept.
In order to facilitate the more convenient use of erythrene in anemia patients, Sansheng Pharmaceuticals has developed a pre-filling needle of rHuEPO to help anemia patients inject erythrene anywhere, anytime, as easily as insulin injections from diabetics, greatly improving the quality of life and mental outlook of patients, so that anemia patients return to an energetic free life.
, the development of long-acting rHuEPO, which helps patients reduce the number of injections, is already on the agenda for Sansheng Pharmaceuticals.
Ebio pre-charged needle rHuEPO as a classic biopharmaceutical, with new dosage forms and more to be explored in the heart, kidney and other multi-organ clinical benefits and other innovative research direction to attract the attention of clinicians and anemia patients.
as the legendary founder of the industry, we believe that Sansheng Pharmaceuticals' continued growth will create a better future for anaemia patients and society in China.
references: Wang Fangshen, Wang Long. A Brief History of Insulin Development. Chinese Journal of Medical History, 2014, 44 (4): 218-222. LIN FK, SUGGS S, LIN C H, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A, 1985, 82 (22): 7580-7584. SALAMIN O, KUURANNE T, SAUGY M, et al. Erythropoietin as a performance-enhancing drug: Its mechanistic basis, detection, and potential adverse effects. Mol Cell Endocrinol, 2018, 464: 75-87. Lin Shan-. Chronic kidney disease anemia . . . Beijing: Concord Medical University Press, 2019: 174-175. JACOBS K, SHOEMAKER C, RUDERSDORF R, et al. Isolation and characterization of genomics and cDNA clones of human erythropoietin. Nature, 1985, 313 (6005): 806-810. JELKMANN W. Erythropoietin after a century of research: younger than ever. Eur J Haematol, 2007, 78 (3): 183-205. JELKMANN W. Developments in the therapeutic use of erythropoiesissing agents. Br J Haematol, 2008, 141 (3): 287-297. Zhu Dayan. Physiology, 8th Edition. Beijing: People's Health Press, 2013: 60-61. LANKHORST CE, WISH JB. Anemia in renal disease: diagnosis and management . Blood Rev, 2010, 24 (1): 39-47. GROS.